Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,174.00    -24.00 (-1.09%)
Bid:
2,188.00
Ask:
2,192.00
Spread: 4.00 (0.183%)
Market Cap: £1.44b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Genus Chief Executive Transition

25 Mar 2019 07:00

RNS Number : 8056T
Genus PLC
25 March 2019
 

For Immediate Release 25 March 2019

 

Genus plc('Genus', or the 'Company')

Genus Chief Executive Transition

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Karim Bitar, Chief Executive Officer, will be stepping down from the Board from 16 September 2019. Karim will be taking the Chief Executive Officer position at ConvaTec Group Plc from 30 September 2019. Karim has committed to remain with Genus and continue in his role until 16 September, to achieve an orderly succession and transition process, while continuing to drive business performance.

"During Karim's eight years at Genus as Chief Executive, the Company has been transformed into a world-leading animal genetics company, truly fulfilling its vision to pioneer animal genetic improvement to help nourish the world. He has led the Company's transformation and is leaving the Company in excellent shape with a world-class leadership team, world-class genetics and innovative technology platforms to enable us to pursue many exciting global opportunities," said Bob Lawson Chair of Genus. "His legacy is the creation of an outstanding global team that will sustain the Company's growth, while serving customers with an unparalleled range of products and services. Karim has provided the Company with many years of strong leadership, and the Board and I remain excited by the Company's future prospects. On behalf of the Board and all at Genus, I wish Karim well for the future and thank him for his considerable contribution during his time with the Company."

Karim Bitar said "It has been a great privilege to lead such a talented group of people and develop a leading global agricultural biotechnology company focused on animal genetics. Genus is in a very strong strategic and financial position, with significant growth prospects and I will miss the team tremendously when I eventually leave in September."

The Board has commenced a search to identify his successor and a further announcement will be made in due course. 

For further information please contact:

Genus

Tel: +44(0)1256 345970

Bob Lawson, Chair

 

Stephen Wilson, Group Finance Director

 

Buchanan

Tel: +44(0)207 466 5000

Charles Ryland /Chris Lane/Sophie Wills

 

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of Karim Bitar's terms of departure are still to be finalised. Any such terms will be consistent with the Company's approved Directors Remuneration Policy. Details of any payments to be made to Karim will be posted on the Company's website, in accordance with section 430(2B) Companies Act 2006. This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. The person responsible for making this announcement on behalf of the Group is Dan Hartley (General Counsel and Company Secretary).

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUMGWUPBGBC
Date   Source Headline
16th Jun 20268:28 amRNSHolding(s) in Company
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.